CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 77.3% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Vir Biotechnology VIR

VirBiotechnology live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

VirBiotechnology news

Laatste marktnieuws

Toon meer
N/A
Noah Lee 2025 Jul 03, 08:35

Wall Street Strategist: Potential $100B+ Stock Market Influx Coming

N/A
Sophia Claire 2025 Jul 03, 08:35

Euro Surges in Foreign Exchange Options Market Amid Bullish Sentiment

N/A
Emma Rose 2025 Jul 03, 08:35

AI Podcast: The Pennsylvania Plan - Domestic Investors to the Rescue?

N/A
liam james 2025 Jul 03, 08:35

AI Podcast: Dollar Weakens Amid Fed Chair Uncertainty

N/A
liam james 2025 Jul 03, 08:35

JPMorgan Model Predicts Stock Market Upswing: An AI Podcast Breakdown

N/A
Ava Grace 2025 Jul 03, 08:35

Dollar Index Plummets Amid Fed Independence Concerns

N/A
liam james 2025 Jul 03, 07:35

AI Podcast: Decoding Economic Indicators and Fed Policy

N/A
Sophia Claire 2025 Jul 03, 07:35

AI Podcast: S&P 500 Hits Record High, Sparking Market Bubble Fears

Info

Spread

0.05

Spread (%)

0.9242 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Donderdag

13:31 - 16:59

Maandag

13:31-19:59

Dinsdag

13:31-19:59

Woensdag

13:31-19:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

750632320

Uitstaande aandelen

138238000

Datum winstcijfer (volgende)

0000-00-00

Div. rend.

Ex-dividenddatum

Jaarlijks verwachte dividendpercentage

0

Jaarlijks verwachte dividendrendement

0

Winst per aandeel

-4.23

Meer informatie over dit instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten

latest_education_articles

Toon meer
Trustpilot